C5b-9-activated, Kv1.3 channels mediate oligodendrocyte cell cycle activation and dedifferentiation

Experimental and Molecular Pathology

Volumn 91, Issue 1, 2011, Pages 335-345

  Tegla, Cosmin A ^a,b   Cudrici, Cornelia ^a   Rozycka, Monika ^a   Soloviova, Katerina ^a   Ito, Takahiro ^a   Singh, Anil K ^a   Khan, Aamer ^a   Azimzadeh, Philippe ^a   Andrian Albescu, Maria ^a   Khan, Anver ^a   Niculescu, Florin ^a   Rus, Violeta ^a   Judge, Susan I V ^a,b   Rus, Horea ^a,b,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Multiple Sclerosis Center of Excellence   (United States)

Author keywords

C5b 9; Complement activation; Multiple sclerosis; Oligodendrocyte; Voltage gated potassium channels

Indexed keywords

COMPLEMENT COMPONENT C5B; COMPLEMENT COMPONENT C5B6; COMPLEMENT MEMBRANE ATTACK COMPLEX; DNA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 3; MYELIN BASIC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; POTASSIUM CHANNEL KV1.3; PROTEIN KINASE B; PROTEOCHONDROITIN SULFATE; PROTEOLIPID PROTEIN; SCORPION VENOM; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL CYCLE PHASE; CELL VIABILITY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; NERVE CELL DIFFERENTIATION; NEWBORN; NONHUMAN; OLIGODENDROGLIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; RNA METABOLISM; SIGNAL TRANSDUCTION; STEM CELL;

ANIMALS; ANIMALS, NEWBORN; CELL CYCLE; CELL DEDIFFERENTIATION; CELLS, CULTURED; COMPLEMENT MEMBRANE ATTACK COMPLEX; HUMANS; KV1.3 POTASSIUM CHANNEL; MULTIPLE SCLEROSIS; OLIGODENDROGLIA; POTASSIUM CHANNEL BLOCKERS; RATS; RATS, SPRAGUE-DAWLEY; SCORPION VENOMS;

SCORPIONES;

EID: 79955689127     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2011.04.006     Document Type: Article

References (45)

1. Attali B., et al. Characterization of delayed rectifier Kv channels in oligodendrocytes and progenitor cells. J. Neurosci. 1997, 17:8234-8245.
2. Bacia A., et al. K+ channel blockade impairs remyelination in the cuprizone model. Glia 2004, 48:156-165.
3. Barnett M.H., Prineas J.W. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 2004, 55:458-468.
4. Barres B.A., Raff M.C. Axonal control of oligodendrocyte development. J. Cell Biol. 1999, 147:1123-1128.
5. Bever C.T., Judge S.I. Sustained-release fampridine for multiple sclerosis. Expert Opin. Investig. Drugs 2009, 18:1013-1024.
6. Billon N., et al. Normal timing of oligodendrocyte development depends on thyroid hormone receptor alpha 1 (TR{alpha}1). EMBO J. 2002, 21:6452-6460.
7. Breij E.C.W., Brink B.P., Veerhuis R., Van den Berg C., Vloet R., Yan R., Dijkstra C.D., Van der Valk P., Bö L. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann. Neurol. 2008, 63:16-25.
8. Carney D.F., et al. Elimination of terminal complement intermediates from the plasma membrane of nucleated cells: the rate of disappearance differs for cells carrying C5b-7 or C5b-8 or a mixture of C5b-8 with a limited number of C5b-9. J. Immunol. 1985, 134:1804-1809.
9. Chittajallu R., et al. Regulation of Kv1 subunit expression in oligodendrocyte progenitor cells and their role in G1/S phase progression of the cell cycle. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:2350-2355.
10. Colley B.S., et al. Neurotrophin B receptor kinase increases Kv subfamily member 1.3 (Kv1.3) ion channel half-life and surface expression. Neuroscience 2007, 144:531-546.
11. Compston D.A., et al. Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathol. Appl. Neurobiol. 1989, 15:307-316.
12. Cragg M.S., et al. Complement mediated cell death is associated with DNA fragmentation. Cell Death Differ. 2000, 7:48-58.
13. Cudrici C., et al. C5b-9 protects oligodendrocytes apoptosis by regulating BH-3-only proapoptotic proteins. FASEB J. 2005, 19:A324.
14. Cudrici C., et al. C5b-9 terminal complex protects oligodendrocytes from apoptotic cell death by inhibiting caspase-8 processing and up-regulating FLIP. J. Immunol. 2006, 176:3173-3180.
15. Cudrici C., et al. Complement C5 regulates the expression of insulin-like growth factor binding proteins in chronic experimental allergic encephalomyelitis. J. Neuroimmunol. 2008, 203:94-103.
16. Datta S.R., et al. Cellular survival: a play in three Akts. Genes Dev. 1999, 13:2905-2927.
17. El-Kholy W., et al. The phosphatidylinositol 3-kinase inhibitor LY294002 potently blocks K(V) currents via a direct mechanism. FASEB J. 2003, 17:720-722.
18. Fosbrink M., et al. Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial cells. Exp. Mol. Pathol. 2009, 86:87-94.
19. Ghiani C.A., et al. Voltage-activated K+ channels and membrane depolarization regulate accumulation of the cyclin-dependent kinase inhibitors p27(Kip1) and p21(CIP1) in glial progenitor cells. J. Neurosci. 1999, 19:5380-5392.
20. Goodman A.D., et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009, 373:732-738.
21. Guo T.B., et al. Insulin-activated, K+-channel-sensitive Akt pathway is primary mediator of ML-1 cell proliferation. Am. J. Physiol. Cell Physiol. 2005, 289:C257-C263.
22. Linington C., et al. Immunohistochemical localisation of terminal complement component C9 in experimental allergic encephalomyelitis. Acta Neuropathol. (Berl.) 1989, 79:78-85.
23. Lucchinetti C., et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47:707-717.
24. Nauta A.J., et al. The membrane attack complex of complement induces caspase activation and apoptosis. Eur. J. Immunol. 2002, 32:783-792.
25. Niculescu F., et al. Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complexes is G protein dependent. J. Immunol. 1997, 158:4405-4412.
26. Niculescu F., et al. Sublytic C5b-9 induces proliferation of human aortic smooth muscle cells: role of mitogen activated protein kinase and phosphatidylinositol 3-kinase. Atherosclerosis 1999, 142:47-56.
27. Niculescu F., et al. Tyrosine phosphorylation and activation of Janus kinase 1 and STAT3 by sublytic C5b-9 complement complex in aortic endothelial cells. Immunopharmacology 1999, 42:187-193.
28. Niculescu F., et al. C5b-9 terminal complement complex assembly on apoptotic cells in human arterial wall with atherosclerosis. Exp. Mol. Pathol. 2004, 76:17-23.
29. Papadimitriou J.C., et al. Quantitative analysis of adenine nucleotides during the prelytic phase of cell death mediated by C5b-9. J. Immunol. 1991, 147:212-217.
30. Papadimitriou J.C., et al. Ultrastructural studies of complement mediated cell death: a biological reaction model to plasma membrane injury. Virchows Arch. 1994, 424:677-685.
31. Rus H.G., et al. Sublytic complement attack induces cell cycle in oligodendrocytes. J. Immunol. 1996, 156:4892-4900.
32. Rus H., et al. Terminal complement complexes induce cell cycle entry in oligodendrocytes through mitogen activated protein kinase pathway. Immunopharmacology 1997, 38:177-187.
33. Rus H., et al. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11094-11099.
34. Rus H., et al. The complement system in central nervous system diseases. Autoimmunity 2006, 39:395-402.
35. Scolding N.J., et al. Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature 1989, 339:620-622.
36. Soane L., et al. Inhibition of oligodendrocyte apoptosis by sublytic C5b-9 is associated with enhanced synthesis of bcl-2 and mediated by inhibition of caspase-3 activation. J. Immunol. 1999, 163:6132-6138.
37. Soane L., et al. C5b-9 terminal complement complex protects oligodendrocytes from death by regulating Bad through phosphatidylinositol 3-kinase/Akt pathway. J. Immunol. 2001, 167:2305-2311.
38. Solanky M., et al. Proliferating oligodendrocytes are present in both active and chronic inactive multiple sclerosis plaques. J. Neurosci. Res. 2001, 65:308-317.
39. Soliven B., et al. Expression and modulation of K+ currents in oligodendrocytes: possible role in myelinogenesis. Dev. Neurosci. 1989, 11:118-131.
40. Storch M.K., et al. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann. Neurol. 1998, 43:465-471.
41. Tang D.G., et al. Lack of replicative senescence in cultured rat oligodendrocyte precursor cells. Science 2001, 291:868-871.
42. Trapp B.D., et al. Differentiation and death of premyelinating oligodendrocytes in developing rodent brain. J. Cell Biol. 1997, 137:459-468.
43. Vautier F., Belachew S., Chittajallu R., Gallo V. Shaker-type potassium channel subunits differentially control oligodendrocyte progenitor proliferation. Glia 2004, 48:337-345.
44. Wilson H.C., et al. Co-expression of PDGF alpha receptor and NG2 by oligodendrocyte precursors in human CNS and multiple sclerosis lesions. J. Neuroimmunol. 2006, 176:162-173.
45. Zwaka T.P., et al. The terminal complement complex inhibits apoptosis in vascular smooth muscle cells by activating an autocrine IGF-1 loop. FASEB J. 2003, 17:1346-1348.